We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00850993
Recruitment Status : Terminated (To redefine study population)
First Posted : February 25, 2009
Results First Posted : August 29, 2014
Last Update Posted : August 29, 2014
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to determine if an experimental drug, stannsoporfin, is safe and effective in the treatment of hyperbilirubinemia in hemolyzing neonates.

Condition or disease Intervention/treatment Phase
Hyperbilirubinemia, Neonatal Drug: stannsoporfin Other: Saline Phase 2

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 63 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2b, Multicenter, Single-dose, Blinded, Randomized, Placebo-controlled, Dose-escalation, Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia
Study Start Date : August 2008
Primary Completion Date : June 2011
Study Completion Date : May 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Jaundice
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Stannsoporfin
3 sequential cohorts of approximately 24 subjects will be recruited. Subjects in the first cohort who are randomized to receive active drug treatment will receive a single dose of 1.5 mg/kg by IM injection. Subjects in the second and third cohorts will receive 3.0 and 4.5 mg/kg, respectively.
Drug: stannsoporfin
single IM injection of 1.5, 3.0, or 4.5 mg/kg
Placebo Comparator: Placebo (Saline)
Cohort of approximately 24 subjects will be recruited.
Other: Saline
Normal saline (0.9%) solution

Outcome Measures

Primary Outcome Measures :
  1. The Primary Efficacy Endpoint Was the Change in Adjusted Total Serum Bilirubin (TSB) From Baseline to 48 Hours After Treatment. [ Time Frame: 48 hours after injection ]

    The primary efficacy endpoint was the change in adjusted TSB from baseline to 48 hours after treatment.

    The adjusted Total Serum Bilirubin (TSB) was a calculation of the percentage difference of the TSB level from the age-specific threshold for PT initiation per the AAP Guidelines, ie, an indication of the distance below the PT threshold at the time.

Secondary Outcome Measures :
  1. Change From Baseline in Unadjusted Total Serum Bilirubin (TSB) at 48 Hours (ITT Population [ Time Frame: 48 hrs ]
    Change from Baseline in Unadjusted TSB at 48 Hours (ITT Population)

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   up to 48 Hours   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Term and late preterm subjects
  • Risk factors for hemolytic disease to include ABO blood type incompatibility or Rh incompatibility (anti-C, c, D, E, or e, or G6PD deficiency
  • A minimum birth weight of 2500 g (5.5 lbs)
  • Enrollment within 2 mg/dL below the Total Serum Bilirubin (TSB) threshold for PhotoTherapy (PT) per the AAP Guidelines at up to 12 hours of age or within 3 mg/dL below the threshold for PhotoTherapy (PT) at >12 to 48 hours of age, inclusive
  • Randomization and treatment cannot take place until the infant is within 1 mg/dl below the threshold for PhotoTherapy (PT) per the American Association Pediatrics (AAP) Guidelines at up to 12 hours of age or within 2 mg/dL below the threshold for PT at >12 to 48 hours of age, inclusive

Exclusion Criteria:

  • Treatment or need for treatment in the neonate with medications that may prolong the QT interval, family history of Long QT syndrome or family history of Sudden Infant Death Syndrome
  • Risk factors for porphyrias, including family history
  • Apgar score ≤6 at age 5 minutes
  • Significant congenital anomalies or infections
  • Cardiorespiratory distress
  • Any abnormal auditory or ophthalmologic findings
  • Any excess risk of requiring surgery or exposure to operating room lights in the foreseeable future
  • Clinically significant abnormalities on screening laboratory evaluation
  • Use of photosensitizing drugs or agents
  • Use of intravenous immunoglobulin (IVIG) or albumins
  • Other serious morbid conditions, eg, pulmonary disease, cardiovascular disease
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00850993

United States, California
Arrowhead Regional Med Center
Colton, California, United States, 92324
UCSD Medical Center
San Diego, California, United States, 92103
United States, Hawaii
Kapi'olani Medical Center for Women and Children
Honolulu, Hawaii, United States, 96826
United States, Kentucky
University of Louisville
Louisville, Kentucky, United States, 40202
United States, New York
Westchester Medical Center
Valhalla, New York, United States, 10595
United States, North Carolina
ECU Brody School of Medicine
Greenville, North Carolina, United States, 27834
United States, Ohio
St. Vincent Mercy Children's Hospital
Toledo, Ohio, United States, 43608
United States, Pennsylvania
Drexel University College of Medicine, Clinical Research Group
Philadelphia, Pennsylvania, United States, 19102
Albert Einstein Medical Center
Philadelphia, Pennsylvania, United States, 19141
Jan Bizel University Hospital No. 2; Department of Neonatal, Preemies and Neonatal Intensive Care
Bydgoszcz, Poland, 85-168
Neonatal Department Warsaw Medical University
Warszawa, Poland, 00-315
Research Institute of Polish Mother's Health Center
Łódź, Poland, 93-338
Hospital Vall D´Hebrón
Barcelona, Spain, 08035
Hospital Clinic i Provincial
Barcelona, Spain, E-08036
Complejo Hospitalario Universitario A Coruña
La Coruña, Spain, 15006
Hospital Doce de Octubre
Madrid, Spain, 28041
Hospital La Paz
Madrid, Spain, 28046
University Hospital Santiago de Compostela-L Coruna
Santiago de Compostela, Spain, 15706
Municipal Medical Institution "Regional pediatric clinical hospital #1", Department of pathology of the newborns; Bukovynian State Medical University, Department of Pediatrics and Children's Infectious Diseases
Chernivtsi, Ukraine, 58023
National Pediatric Specialized Hospital "OHMATDYT".
Kiev, Ukraine, 1135
State Institution "Institute of Pediatrics, Obstetrics and Gynecology of the Academy of Medical Science of the Ukraine", Neonatology Department
Kiev, Ukraine, 4050
Municipal Institution "Odessa regional clinical hospital", Department of pathology of the newborns and premature infants; Odessa State Medical University; Chair of Pediatrics #1 and Neonatology
Odessa, Ukraine, 65031
Vinnytsia regional pediatric hospital, Department of pathology of the newborns, Vinnytsia National Medical University named after M.I.Pirogov, Chair of Pediatrics #1
Vinnitsa, Ukraine, 21029
Sponsors and Collaborators
InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
Principal Investigator: M. Jeffrey Maisels, MB, BCh William Beaumont Hospitals
More Information

Responsible Party: InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
ClinicalTrials.gov Identifier: NCT00850993     History of Changes
Other Study ID Numbers: 64,185-202
2009-017434-45 ( EudraCT Number )
First Posted: February 25, 2009    Key Record Dates
Results First Posted: August 29, 2014
Last Update Posted: August 29, 2014
Last Verified: August 2014

Keywords provided by InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company:

Additional relevant MeSH terms:
Hyperbilirubinemia, Neonatal
Pathologic Processes
Infant, Newborn, Diseases
Tin mesoporphyrin
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action